𝐍𝐈𝐏𝐑𝐎 – 𝐉𝐌𝐈 𝐉𝐨𝐢𝐧𝐭 𝐕𝐞𝐧𝐭𝐮𝐫𝐞: 𝐓𝐡𝐞 𝐓𝐫𝐞𝐧𝐝 𝐒𝐞𝐭𝐭𝐞𝐫 𝐨𝐟 𝐉𝐚𝐩𝐚𝐧𝐞𝐬𝐞 𝐄𝐪𝐮𝐢𝐭𝐲 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐢𝐧 𝐁𝐚𝐧𝐠𝐥𝐚𝐝𝐞𝐬𝐡 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐒𝐞𝐜𝐭𝐨𝐫
JMI Group receives USD80 million FDI from Japan.Bangladesh's leading conglomerate in the pharmaceuticals and medical device sector, JMI Group has completed its 12 years journey with NIPRO Corporation, a Japan-based leading global healthcare company. In this journey, five entities under NIPRO-JMI Joint Venture has received 80 million US Dollar (Tk680 crore) in foreign direct investment (FDI) from Japan. Since our independence, Japan is always being a big development partner of Bangladesh.
We have achieved trust and confidence of Japanese Investors by producing quality products. JMI Group has very strong business tie up with NIPRO Corporation, a Japanese giant in Pharmaceuticals, Medical Devices Manufacturing and Pharma Packaging business.
Entrepreneurs in the country are now investing in new sectors where sophistication is a prerequisite, such as medical device manufacturing.
"The country's development has been ongoing in a structured way," he told the celebration of a 12-year partnership between pharmaceutical company JMI Group and Japan-based Nipro Corporation. The duo jointly organized the event styled "NIPRO-JMI Joint Venture: The trend setter of Japanese equity investment in Bangladesh's healthcare sector" at Pan Pacific Sonargaon Dhaka.The partnership started off with the manufacturing of medical devices in 2011 and later expanded to healthcare services, pharmaceuticals and product marketing sectors, said a press release.
Around 5,500 employees currently work at five business entities under the joint venture initiative, which received $80 million (Tk 680 crore) foreign direct investment from Japan. Asaduzzaman Khan Kamal, home affairs minister, Planning Minister MA Mannan , ITO Naoki, Japanese ambassador to Bangladesh, Md Jabed Iqbal Pathan, chairman of JMI Group, were present.